Drug Trial Radar · NCT05372367
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Aug 11, 2022
Primary completion
Jul 17, 2024
Study completion Apr 29, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open for adults with advanced cancer (solid tumours). This is a study for people for whom previous treatment was not successful. This study tests a medicine called BI 907828. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. The purpose of this study is to find out whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor. This study uses an OATP inhibitor called rifampicin and a CYP3 inhibitor called itraconazole. In clinical practice, rifampicin is used as an antibiotic. Itraconazole is used to treat fungal infections. Participants are divided into 2 groups: a rifampicin group and an itraconazole group. Every participant takes BI 907828 as a tablet every 3 weeks. This is called a cycle. * Rifampicin group: In addition to BI 907828, participants take 1 tablet of rifampicin in the second cycle. * Itraconazole group: In addition to BI 907828, participants take itraconazole tablets for 20 days starting 1 week after the second cycle begins Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors take blood samples from the participants to compare the amount of BI 907828 in the blood when it is taken alone and when participants also take rifampicin. Doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Solid Tumors
Interventions
BI 907828Drug
BI 907828
RifampicinDrug
Rifampicin
ItraconazoleDrug
Itraconazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- Group 1: Area under the concentration-time curve of BI 907828 in plasma over the time interval from 0 to 24 hours (AUC 0-24)Time frame: up to 24 hours
- Group 1: Maximum measured concentrations of BI 907828 in plasma (C max)Time frame: up to 15 days
- Group 2: Area under the concentration-time curve of BI 907828 in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz)Time frame: up to 15 days
- Group 2: Maximum measured concentrations of BI 907828 in plasma (C max)Time frame: up to 15 days
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Wilrijk - HOSP GZA (St-Augustinus)
Wilrijk, Belgium
Hospital Quiron. I.C.U.
Barcelona, Spain
Hospital Universitari Vall D Hebron
Barcelona, Spain
Fundación Jiménez Díaz
Madrid, Spain
CIO Clara Campal
Madrid, Spain
Hospital Quirónsalud Madrid
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.